C4 Therapeutics, Inc. (CCCC) P/E Ratio

C4 Therapeutics, Inc. PE Ratio

The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.

• C4 Therapeutics, Inc. pe ratio for the quarter ending 2026-06-30 was -5.65, a change of -4.74 year-over-year.
• C4 Therapeutics, Inc. pe ratio for the quarter ending 2026-03-31 was -2.64, a change of -1.54 year-over-year.
• C4 Therapeutics, Inc. pe ratio for the quarter ending 2025-12-31 was -1.76, a change of 0.65 year-over-year.
• C4 Therapeutics, Inc. pe ratio for the quarter ending 2025-09-30 was -1.38, a change of 2.43 year-over-year.
• C4 Therapeutics, Inc. pe ratio for fiscal 2026 was -5.65.
• C4 Therapeutics, Inc. pe ratio for fiscal 2025 was -1.76, a change of 0.65 from fiscal 2024.
• C4 Therapeutics, Inc. pe ratio for fiscal 2024 was -2.41, a change of 0.16 from fiscal 2023.
• C4 Therapeutics, Inc. pe ratio for fiscal 2023 was -2.58, a change of -0.32 from fiscal 2022.